Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Biofrontera ( (DE:B8FK) ) has shared an announcement.
Biofrontera AG has announced an expected impairment loss between €50 million and €65 million in its unconsolidated accounts due to reduced profit expectations for its subsidiaries, Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH. This will lower the company’s consolidated net earnings for 2025 by approximately €5 million, although it will not affect the consolidated EBITDA or cash position, indicating a significant financial adjustment but maintaining operational stability.
More about Biofrontera
Biofrontera AG operates in the pharmaceutical industry, focusing on the development and commercialization of dermatological products. The company is known for its innovative treatments in skin diseases and has a market presence in various regulated and free markets across Germany.
Average Trading Volume: 3,267
Technical Sentiment Signal: Hold
Current Market Cap: €17.08M
For a thorough assessment of B8FK stock, go to TipRanks’ Stock Analysis page.